Pasithea Therapeutics Corp.
KTTA
$0.57
-$0.03-4.89%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 4.83% | -42.21% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.16% | -19.95% | |||
| Operating Income | -17.16% | 19.95% | |||
| Income Before Tax | -83.79% | 71.62% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -83.79% | 71.62% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -83.79% | 71.62% | |||
| EBIT | -17.16% | 19.95% | |||
| EBITDA | -17.73% | 20.48% | |||
| EPS Basic | -39.36% | 85.11% | |||
| Normalized Basic EPS | -39.35% | 74.67% | |||
| EPS Diluted | -39.36% | 85.11% | |||
| Normalized Diluted EPS | -39.35% | 74.67% | |||
| Average Basic Shares Outstanding | 31.89% | 90.58% | |||
| Average Diluted Shares Outstanding | 31.89% | 90.58% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||